Merck's Heart Failure Drug Preserves Renal Function in Phase III Trial
Posted on: Wednesday, 2 April 2008, 12:00 CDT
Merck & Co. has said that, in a Phase III pilot dose-ranging study of patients with acute heart failure syndrome and renal impairment, treatment with rolofylline administered with intravenous loop diuretics was associated with improved dyspnea and preserved renal function compared to treatment with placebo and intravenous diuretics.
In addition, in a post-hoc analysis, treatment with rolofylline was associated with a trend towards reduced 60-day mortality or hospital readmission for cardiovascular or renal causes. Rolofylline increases renal blood flow and urine production by blocking adenosine-mediated vasoconstriction of the afferent arterioles of the kidneys and inhibiting salt and water reabsorption by the kidney.
Barry Massie, lead investigator of the study, said: "Preserving kidney function is an important goal for improving the prognosis of patients with acute heart failure. We now need to assess in larger clinical trials whether rolofylline can positively affect acute symptoms of heart failure and help preserve renal function."
Source: Datamonitor
Related Articles
- Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure
- Palatin Starts Phase I Trials for Heart Failure Treatment
- Osiris Therapeutics Receives FDA Clearance to Initiate Phase III Pivotal Trial for Prochymal(TM) As a First Line Treatment for Acute Graft Vs. Host Disease
- BioLineRx In-Licenses Novel Drug for the Treatment of Acute Kidney Injury
- Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft Vs. Host Disease
- Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft Vs. Host Disease
- BioAxone Therapeutic Completes Patient Enrollment for Phase I/IIa Trial of Cethrin(R) in Treatment of Acute Spinal Cord Injury
- Structural GenomiX Initiates Phase 2/3 Trial of Troxatyl for the Treatment of Acute Myelogenous Leukemia
- Clinical Issues and Research in Respiratory Failure From Severe Acute Respiratory Syndrome
- Both Inherited Traits and Tumor Mutations Affect Response to Treatment of Acute Lymphoblastic Leukemia
 |
 |
User Comments (0)
RSS Feeds